These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2605831)

  • 21. Hexosaminidase A activity and amyotrophic lateral sclerosis.
    Gudesblatt M; Ludman MD; Cohen JA; Desnick RJ; Chester S; Grabowski GA; Caroscio JT
    Muscle Nerve; 1988 Mar; 11(3):227-30. PubMed ID: 2965300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collagen cross-linking of skin in patients with amyotrophic lateral sclerosis.
    Ono S; Yamauchi M
    Ann Neurol; 1992 Mar; 31(3):305-10. PubMed ID: 1637138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients.
    Shibata N; Kakita A; Takahashi H; Ihara Y; Nobukuni K; Fujimura H; Sakoda S; Sasaki S; Iwata M; Morikawa S; Hirano A; Kobayashi M
    Neurodegener Dis; 2009; 6(3):118-26. PubMed ID: 19372705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methionine adenosyltransferase activity in erythrocytes and spinal cord of patients with sporadic amyotrophic lateral sclerosis.
    Ekegren T; Askmark H; Aquilonius SM; Gomes-Trolin C
    Exp Neurol; 1999 Aug; 158(2):422-7. PubMed ID: 10415148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Scand J Clin Lab Invest; 2007; 67(3):264-9. PubMed ID: 17454840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Survival in amyotrophic lateral sclerosis].
    Alcaz S; Jarebinski M; Pekmezović T; Marinković Z; Apostolski S
    Srp Arh Celok Lek; 1997; 125(1-2):19-23. PubMed ID: 17974351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis.
    Zoccolella S; Simone IL; Lamberti P; Samarelli V; Tortelli R; Serlenga L; Logroscino G
    Neurology; 2008 Jan; 70(3):222-5. PubMed ID: 18195267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
    Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 32. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E; Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s.
    Asai H; Imaoka S; Kuroki T; Monna T; Funae Y
    J Pharmacol Exp Ther; 1996 May; 277(2):1004-9. PubMed ID: 8627510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
    Dupuis L; Corcia P; Fergani A; Gonzalez De Aguilar JL; Bonnefont-Rousselot D; Bittar R; Seilhean D; Hauw JJ; Lacomblez L; Loeffler JP; Meininger V
    Neurology; 2008 Mar; 70(13):1004-9. PubMed ID: 18199832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type].
    Petersen P; Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):443-4. PubMed ID: 2000655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sparteine oxidation is practically abolished in quinidine-treated patients.
    Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
    Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substantial rise in sparteine metabolic ratio during haloperidol treatment.
    Gram LF; Debruyne D; Caillard V; Boulenger JP; Lacotte J; Moulin M; Zarifian E
    Br J Clin Pharmacol; 1989 Feb; 27(2):272-5. PubMed ID: 2713222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
    Nielsen MD; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
    Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
    Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.